This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease) |
| B. Synonyms | Parahemophilia, Factor V deficiency, AC globulin deficiency, Proaccelerin deficiency, Labile factor deficiency |
| C. Adult onset | Not low — severe cases can have spontaneous bleeding from childhood, but mild and moderate cases are discovered incidentally in adulthood through bleeding after surgery, trauma, or delivery or through simultaneous prolongation of PT and APTT; a clear understanding of the contrast between FV deficiency and FV Leiden (a thrombotic predisposition) is needed. |
| 1. History | First described by Paul Arnald Owren in 1947. Named "parahemophilia." FV first named "parahemolysin." Contributed to establishing Owren's coagulation factor classification system (Factor I–V). |
| 2. Causes | F5 gene (1q24.2) variants; autosomal recessive; diverse variants; clear distinction from FV Leiden (Arg506Gln)—the contrast between deficiency and hyperactivation. |
| 3. Genetics | F5 gene 1q24.2; large gene (about 80 kb, 25 exons); A-domain structure (similar to FVIII); contrast with FV Leiden; opposite genetic characteristics of thrombotic and bleeding predisposition. |
| 4. Epidemiology | About 1 per million (congenital severe deficiency); among the rarest group of all rare coagulation factor deficiencies; equal in males and females. |
| 5. Pathophysiology | FV (proaccelerin) is a cofactor of FXa; amplifies the catalytic activity of FXa 1000-fold in the prothrombinase complex (FXa-FVa-Ca²⁺-phospholipid); thrombin generation is markedly reduced in FV deficiency. |
| 6. Symptoms | Pattern of prolongation of both PT and APTT; spontaneous bleeding (intracranial hemorrhage, joints, muscles), excessive bleeding after surgery, menorrhagia, postpartum hemorrhage; symptoms disproportionate to severity. |
| 7. Signs | Simultaneous prolongation of PT and APTT (common pathway deficiency pattern); reduced FV:C; differentiation needed from other causes prolonging both PT and APTT (FX, FII, FI deficiency, DIC, liver disease). |
| 8. Screening | Detection of simultaneous PT and APTT prolongation; differentiation of fibrinogen, FX, FII; single-factor FV:C assay; consider the platelet FV contribution; family testing. |
| 9. Diagnosis | Simultaneous PT and APTT prolongation → differentiation of DIC, liver disease, vitamin K → single-factor FV:C assay → mixing test → F5 gene analysis; check for coexisting FV Leiden. |
| 10. Treatment | Fresh frozen plasma (FFP) is the only main treatment option; platelets (platelets contain FV); cryosupernatant; no dedicated FV concentrate; half-life 12–36 hours. |
| 11. Prognosis | Risk of intracranial hemorrhage in severe cases; treatable with FFP, but the lack of a dedicated concentrate is a treatment limitation; FV inhibitors may develop. |
| 12. Prevention | Preoperative preparation of FFP + platelets; prophylaxis for severe cases (FFP); genetic counseling; immunosuppression if FV inhibitors develop. |
| 13. References | Owren PA 1947 first description and 11 or more other major references. |
The history of Owren disease is a disease name that directly bears the name of the Norwegian hematologist Paul Arnald Owren (1905–1990), and understanding the history of its discovery is the starting point for understanding this disease. In 1947, Owren described a new blood coagulation disorder with a severe bleeding tendency in a young Norwegian woman then in her early 20s. This patient experienced recurrent nosebleeds, gum bleeding, excessive bleeding after surgery, and bruising (contusion hematomas), and showed laboratory findings distinct from hemophilia A and B—prolongation of both prothrombin time (PT) and activated partial thromboplastin time (APTT). Owren confirmed the existence of a new deficient factor not explained by the previously known coagulation factors (prothrombin, fibrinogen, accelerator globulin) and initially named it parahemolysin. This discovery was published that same year as a landmark paper in Acta Medica Scandinavica, and the factor was later standardized as coagulation Factor V.
The disease first described by Owren is also known by the name "parahemophilia." This name means a disease "similar to hemophilia but not hemophilia (para-)." It differs from hemophilia in that, whereas hemophilia A and B are X-linked recessive and expressed mainly in males, FV deficiency is autosomal recessive and expressed equally in males and females. In addition, PT is normal in hemophilia A and B, but in FV deficiency PT is also prolonged, so the coagulation test pattern differs. The name "parahemophilia" is a historical name expressing that this disease has a bleeding tendency like hemophilia but a different mechanism and mode of inheritance, and it is still used in some textbooks and clinical literature. The World Federation of Hemophilia (WFH) avoids this name in official documents and prefers "congenital Factor V deficiency" or "Owren disease," but both names are still used in clinical practice.
Besides describing FV deficiency, Paul Owren left a broader academic legacy in coagulation medicine. He was one of the first scholars to propose a nomenclature assigning systematic numbers to the factors involved in the coagulation process. In Owren's proposal, Factor I was fibrinogen, Factor II prothrombin, Factor III thromboplastin (tissue factor), Factor IV calcium ion, and Factor V the "parahemolysin" he had discovered. This proposal was adopted by the international nomenclature committee at the 5th meeting of the International Society on Thrombosis and Haemostasis (predecessor of the ISTH) held in Rome in 1954, and became the foundation of the Factor I–XIII nomenclature used today. Factor V as proposed by Owren is still used as is, and in this respect Owren disease occupies a unique place in the history of coagulation medicine in that the name of its discoverer survives not only in the disease name but also in the numbering system of the discovered factor.
In the history of the FV deficiency discovered by Owren—Owren disease, parahemophilia—the most important additional discovery of the 1990s was the identification of the FV Leiden variant. In 1994, Bertina et al. of Leiden University in the Netherlands discovered the Arg506Gln variant of the FV gene (FV Leiden) in patients with a hereditary thrombotic tendency. This variant prevents FV from being inactivated by APC (activated protein C), so that FVa remains persistently in the activated state, producing the opposite clinical result to Owren disease (FV deficiency)—an increased thrombotic tendency. A peculiar characteristic of the F5 gene is that variants of the same gene appear as deficiency in one direction and hyperactivation in the other, with opposite clinical results of bleeding versus thrombosis. The FV Leiden variant is the most common hereditary thrombotic predisposition, found in about 5% of Western Caucasians, whereas FV deficiency (Owren disease) is very rare at 1 per million. This stark contrast is used as an important example in teaching coagulation biology.
Owren disease (congenital FV deficiency) is caused by pathogenic variants of the F5 gene located on the long arm of chromosome 1 at 1q24.2. The F5 gene is a large gene of about 80 kb consisting of 25 exons and encodes the mature FV protein (2,196 amino acids, molecular weight about 330 kDa). The mode of inheritance is autosomal recessive, and complete deficiency is expressed in the homozygous or compound heterozygous state. Heterozygous carriers (FV:C about 40–65%) usually have no clinical bleeding, but some may show a mild bleeding tendency or increased postoperative bleeding. To date, more than about 200 pathogenic F5 variants have been reported, of diverse types including missense, nonsense, splicing, insertion, and deletion. Variants tend to cluster in the B domain (the connecting region between the heavy chain and light chain) and the A domains, and these variants impair FV functions such as protein folding, secretion, activation, or inactivation by APC.
In clinical practice it is important to clearly distinguish FV deficiency (Owren disease) from FV Leiden. FV Leiden (FV Arg506Gln, rs6025) is a gain-of-function variant of the F5 gene that eliminates the Arg506 cleavage site for APC (activated protein C), preventing inactivation of FVa. The risk of venous thromboembolism is known to increase about 3–8-fold in heterozygous FV Leiden carriers and about 50–100-fold in homozygotes. In contrast, FV deficiency (Owren disease) is due to loss-of-function variants that reduce FV production itself, causing a bleeding tendency. FV Leiden is a polymorphism occurring at a very high frequency of about 5% in the general population (Western Caucasian populations), whereas FV deficiency is a very rare disease at 1 per million. In FV Leiden heterozygotes, FV:C is usually normal or slightly elevated, but in heterozygous carriers of FV deficiency, FV:C is reduced to about 40–65%. Rarely, in compound heterozygous patients carrying one FV Leiden variant and one FV deficiency variant, a complex situation may arise in which only FV Leiden is expressed, so that there is a thrombotic tendency yet FV:C is low.
FV and FVIII have many molecular structural similarities, suggesting that the two factors derive from a common evolutionary ancestor. Both FV and FVIII have an A1-A2-B-A3-C1-C2 domain structure. The A domains resemble the A domains of ceruloplasmin, a copper-binding oxidoreductase, and the C domains resemble the C domains of galactose oxidase. Because the B domain has almost no structural function in either factor, B-domain deleted recombinant proteins have been developed for both FV and FVIII. However, FV and FVIII differ importantly in function. FVIII functions as a cofactor of FIXa in the intrinsic tenase (FIXa-FVIIIa), whereas FV functions as a cofactor of FXa in the prothrombinase (FXa-FVa). This molecular similarity is also the basis for research to develop molecules that can replace FV function in the treatment of FV deficiency.
A point requiring special consideration in the diagnosis and treatment of Owren disease is that platelets store a considerable amount of FV internally. About 20–25% of total blood FV is stored in platelet alpha granules (α-granules) and is secreted upon platelet activation. Platelet FV is synthesized from the same F5 gene as plasma FV but has the characteristic of being taken up and stored in endothelial cell–derived granules of platelets. In patients with congenital FV deficiency, some platelet FV may remain even when plasma FV:C is 0, which is explained as one of the reasons why some patients with severe FV deficiency show a milder bleeding phenotype than expected. Conversely, in patients whose platelet FV storage is also abnormal, both plasma FV:C and platelet FV must be replaced, and in this case platelet transfusion (platelets contain FV) is used as an additional treatment.
The F5 gene is located on the long arm of chromosome 1 at 1q24.2; its official HGNC symbol is F5 and its Entrez Gene ID is 2153. The gene is about 80 kb in total length and consists of 25 exons, smaller than the FVIII gene (186 kb) but still quite large. The mature FV protein consists of 2,196 amino acids (molecular weight about 330 kDa), with an A1-A2-B-A3-C1-C2 domain arrangement. The A1, A2, and A3 domains each have about 350 amino acids and similar structures. The B domain is very large (about 836 amino acids) and has several potential O-glycosylation sites, but it is not directly required for cofactor function. Activation of FV by thrombin and FXa occurs by cleavage of the B domain (R709, R1018, R1545), and activated FVa is a heterodimer in which the light chain (A3-C1-C2 domains) and heavy chain (A1-A2 domains) are linked by Ca²⁺-dependent noncovalent bonds.
More than 200 pathogenic variants have been reported in the F5 gene, distributed across the entire protein domain. In terms of functional effect, variants fall into several types. Variants impairing protein synthesis/secretion (CRM−): due to nonsense variants, frameshifts, or large deletions, FV protein is not produced or is lost through nonsense-mediated decay (NMD). Misfolding variants: due to missense variants, FV protein is produced but folded abnormally and retained in the endoplasmic reticulum, so it is not secreted. Dysfunctional variants (CRM+): missense variants in which production and secretion of FV protein are normal but functional domains such as FXa binding, the APC inactivation site, and the platelet binding site are affected, impairing the cofactor function of FV. B-domain variants: most B-domain variants do not directly affect the cofactor function of FV, but some affect the plasma half-life of FV protein or platelet storage. These diverse variant types form the molecular background for the disproportion in clinical severity of FV deficiency.
Because FV deficiency (Owren disease) is autosomal recessive, complete deficiency occurs in 25% of children only when both parents are heterozygous carriers. In contrast, FV Leiden (a thrombotic predisposition) is inherited such that clinical risk increases even in heterozygotes, so frequent heterozygous carriers become the main clinical problem of thrombotic risk. Asking whether these two F5 variants ever occur together is a clinically meaningful question. In fact, cases have been reported in which the same patient has an FV deficiency variant on one allele and FV Leiden on the other allele (compound heterozygosity). In these patients, FV:C is low at about 40–65% (contribution of the FV deficiency allele), and all functioning FV consists of FV Leiden, showing APC resistance (increased thrombotic risk). Thus, complex situations exist in which a bleeding predisposition (FV deficiency) and a thrombotic predisposition (FV Leiden) are expressed simultaneously from the same gene, and both need to be tested in clinical evaluation.
A rare condition with a clinically important genetic link related to Owren disease (FV deficiency) is Combined FV+FVIII deficiency (F5F8D). This condition is caused not by variants in the F5 or F8 genes themselves but by variants in the LMAN1 (lectin mannose-binding 1) or MCFD2 (multiple coagulation factor deficiency 2) genes. Because LMAN1 and MCFD2 form a cargo complex jointly required for transport of FV and FVIII from the endoplasmic reticulum (ER) to the Golgi apparatus, variants in these genes reduce secretion of both FV and FVIII simultaneously. As a result, a bleeding disorder occurs in which FV:C and FVIII:C are both simultaneously reduced to about 5–30 IU/dL. Because F5F8D has a different cause and mode of inheritance from pure FV deficiency (Owren disease), it is important to distinguish between these two causes when both FV and FVIII are clinically reduced.
The prevalence of the severe form (FV:C <1 IU/dL) of Owren disease (congenital FV deficiency, parahemophilia) is about 1 per million, placing it, together with FXIII deficiency, in the rarest category of all coagulation factor deficiencies. In the World Federation of Hemophilia (WFH) 2023 annual survey, the number of officially registered FV deficiency patients worldwide was reported at about 400–600, an underestimate reflecting only a tiny fraction of actual patients. Including mild and moderate deficiency (FV:C 1–50 IU/dL), the prevalence is higher, but mild cases are often undiagnosed because they are asymptomatic or have minor symptoms. Because inheritance is autosomal recessive, the male-to-female ratio is 1:1.
Owren disease has a higher risk of occurrence in populations where consanguineous marriage is common. Relatively many cases have been reported in Middle Eastern and South Asian populations such as Iran, Iraq, Lebanon, India, Pakistan, and Turkey. The high frequency in these populations is the result of the proportion of FV deficiency carriers in the general population being amplified by consanguineous marriage. Specific founder variants have sometimes been reported in specific populations, but clear concentration of founder variants as in FVII deficiency or FXIII deficiency is less evident in FV deficiency. In Korea, FV deficiency is a very rare disease, and systematic national registry data are lacking. Reported Korean cases are at the level of case reports, mainly cases discovered through neonatal or childhood bleeding or incidentally on preoperative testing in adults.
The age at diagnosis of FV deficiency varies with severity. In severe deficiency (FV:C <1 IU/dL), it is sometimes detected early through umbilical cord bleeding in the neonatal period, intracranial hemorrhage in infancy, or spontaneous joint and muscle bleeding in childhood. Moderate cases (1–10 IU/dL) are diagnosed from childhood through adulthood, mainly through excessive bleeding after surgery or trauma, and in women are sometimes discovered through menorrhagia or postpartum hemorrhage. Mild cases (FV:C >10 IU/dL) are often diagnosed incidentally when simultaneous PT and APTT prolongation is found on preoperative testing in adulthood. Heterozygous carriers are mostly asymptomatic and are first identified during family history investigation of FV deficiency. In compound heterozygotes for FV deficiency and FV Leiden, it is sometimes discovered during thrombophilia testing after a thrombotic event.
Although FV deficiency is a bleeding disorder, some reports describe cases of venous thromboembolism in patients with FV deficiency. One possible explanation for this paradoxical situation is that FV functions not only as a cofactor that helps thrombus formation but is also involved in anticoagulant mechanisms (the role of FV as an APC cofactor in the protein C pathway, i.e., FV promoting the action of APC in inactivating FVIII and FVa). The dual role of FV—procoagulant (as a cofactor of FXa) and anticoagulant (as a cofactor of APC)—suggests that in FV deficiency both functions are lost, so the balance between bleeding and thrombosis may change in complex ways. Clinically, however, the main problem of FV deficiency is bleeding, and an increased thrombotic risk is not an established fact.
Coagulation factor V (FV, proaccelerin) is the key cofactor in the reaction that converts prothrombin (FII) to thrombin (FIIa) in the common pathway of blood coagulation. Under normal conditions, FV circulates in plasma as an inactive precursor and is activated to FVa by small amounts of thrombin or FXa. FVa forms a complex with FXa on the phospholipid membrane of the platelet surface, constituting the prothrombinase complex. In the presence of Ca²⁺ and phospholipid, this complex converts prothrombin to thrombin at a rate about 1,000-fold higher than the enzymatic activity of FXa alone. FVa enables this explosive amplification of enzyme activity through a combined mechanism of increasing the binding affinity of FXa for its substrate (prothrombin) and increasing the catalytic turnover of FXa. This is why FV is named "proaccelerin," that is, "the precursor of the accelerator factor."
In FV deficiency, prothrombinase complex formation is incomplete, so thrombin generation is markedly reduced. Both the extrinsic pathway (TF-FVIIa → FXa) and the intrinsic pathway (FIXa-FVIIIa → FXa) ultimately generate FXa, but without FVa this FXa cannot efficiently convert prothrombin to thrombin. Therefore, FV deficiency impairs the common pathway shared by both pathways, prolonging both PT and APTT. This explains the most characteristic coagulation test pattern of FV deficiency—simultaneous prolongation of PT and APTT. Besides FV, the common pathway includes FX, prothrombin (FII), and fibrinogen (FI), and deficiency of any of these likewise produces a pattern of prolongation of both PT and APTT. Therefore, systematic differentiation of common pathway factors in the pattern of simultaneous PT and APTT prolongation is the starting point for diagnosing Owren disease.
Besides its role as a procoagulant cofactor, FV also plays an important role in the activated protein C (APC)–protein S anticoagulant pathway. Normally, APC uses protein S as a cofactor to inactivate FVa by sequential cleavage at Arg506, Arg306, and Arg679. In particular, the initial Arg506 cleavage occurs most rapidly, quickly abolishing the cofactor activity of FVa. In FV Leiden, this Arg506 is replaced by Gln, so the initial cleavage by APC is impeded and FVa remains persistently active. This is the key mechanism by which thrombotic risk increases in patients with FV Leiden. In contrast, in Owren disease (FV deficiency), FVa is absent or very low, so the process of inactivation by APC itself has little significance. In addition, the mechanisms by which the C2 domain of FVa is the structure required for binding to the platelet phospholipid membrane during prothrombinase complex formation, and by which the A2 domain of FV undergoes APC cleavage competitively with FVIII, also show that FV plays a regulatory role beyond that of a simple cofactor.
One reason the clinical bleeding severity of FV deficiency is not always proportional to the plasma FV:C level is the contribution of platelet FV. FV stored in platelet alpha granules is secreted upon platelet activation, forming locally high FVa concentrations on the platelet surface, which contributes to prothrombinase complex formation on the platelet surface. Therefore, even in patients with very low plasma FV:C (less than 1%), if some platelet FV is preserved, thrombin generation is maintained locally at sites of injury where platelet activation occurs, and clinical bleeding may be milder than expected. Conversely, in patients with severely reduced platelet FV storage, more serious bleeding may occur even with similar plasma FV:C. This individual variation in platelet FV is an important factor contributing to the phenotypic diversity of Owren disease.
The clinical bleeding symptoms of Owren disease are proportional to the FV:C level to some extent but show a complex relationship rather than a complete one-to-one correspondence. In severe deficiency (FV:C <1 IU/dL), spontaneous bleeding may occur, the most concerning of which is intracranial hemorrhage. Intracranial hemorrhage is the main cause of death in FV deficiency and tends to be concentrated in infancy and childhood. Spontaneous joint bleeding (hemarthrosis) can also occur in severe deficiency, but there are reports that it is less frequent than in hemophilia A and B. Muscle hematomas also occur not infrequently and may progress to pseudotumors if repeated. In moderate deficiency (1–10 IU/dL), delayed and excessive bleeding after surgery or trauma is mainly the main problem, with unexpected bleeding occurring with tooth extraction, tonsillectomy, general surgery, and so on. In mild deficiency (FV:C >10 IU/dL), it is discovered incidentally through preoperative PT and APTT prolongation, or excessive bleeding appears only with major surgery.
Important bleeding symptoms in women with FV deficiency are menorrhagia and postpartum hemorrhage. Menorrhagia is reported in a considerable number of women with FV deficiency, and excessive blood loss recurring every month sometimes leads to iron deficiency anemia. Because fibrinolytic activity of the endometrium is high, FV deficiency acts synergistically with reduced thrombin generation at sites where unstable fibrin clots form. During pregnancy, FV:C rises slightly physiologically (FV rises to about 100–150 IU/dL in the third trimester of normal pregnancy), so the bleeding risk is relatively lower, but it falls sharply right after delivery, increasing the risk of postpartum hemorrhage. FFP must be prepared to prevent postpartum hemorrhage in both cesarean section and vaginal delivery. Recurrent miscarriage has also been reported in women with FV deficiency, but this is rarer than in fibrinogen deficiency or dysfibrinogenemia.
Mucosal bleeding and skin bleeding are also commonly reported symptoms of Owren disease. Nosebleeds (epistaxis) are one of the most common spontaneous bleeding symptoms, characterized by recurrent and persistent nosebleeds that sometimes do not respond well to compression. Gum bleeding also occurs often, and delayed bleeding after tooth extraction is sometimes the first clue to a diagnosis of FV deficiency. Easy bruising of the skin, in which extensive subcutaneous bleeding occurs even with minor impacts, requires caution because it can be mistaken for child abuse, especially in pediatric patients. In such cases, coagulation tests (PT and APTT prolongation) suggest FV deficiency, so it is important to evaluate underlying coagulation abnormalities in children with skin hematomas. Subconjunctival hemorrhage, hematuria, and bloody stools have also been reported, though rarely.
Umbilical cord bleeding can occur in neonates with severe FV deficiency. It does not always occur as in FXIII deficiency, but it is a quite possible symptom in severe FV deficiency. Intracranial hemorrhage is the most dangerous complication of FV deficiency and can occur spontaneously without trauma or appear in a delayed fashion after a minor head bump. When sudden headache, vomiting, seizures, or altered consciousness occur in infancy or childhood and both PT and APTT are prolonged, common pathway factor deficiency including FV deficiency should be suspected immediately and FV:C measured at the same time as emergency treatment. When intracranial hemorrhage occurs, FV is replaced by urgent FFP administration, and whether neurosurgical intervention is needed is decided according to the size of the intracranial hemorrhage and the neurological status.
The most characteristic coagulation test finding of Owren disease (FV deficiency) is prolongation of both PT and APTT. Because FV is a component of the common pathway on which both the extrinsic pathway (TF-FVIIa → FXa) and the intrinsic pathway (FIXa-FVIIIa → FXa) converge, in FV deficiency the final step of both pathways is impaired and PT and APTT are prolonged together. This pattern also appears in deficiency of other common pathway factors (FX, prothrombin FII, fibrinogen FI), so simultaneous PT and APTT prolongation alone cannot identify FV deficiency. The thrombin time (TT) measures only the step of converting fibrinogen to fibrin, so it is normal in FV deficiency. The platelet count is also normal. This pattern—prolonged PT, prolonged APTT, normal TT, normal platelets—can appear in common pathway factor deficiency, liver disease, DIC, vitamin K deficiency, or inhibitors affecting both PT and APTT, and further testing is needed to identify the cause.
When both PT and APTT are prolonged, systematic differentiation is needed. The first thing to consider is DIC (disseminated intravascular coagulation). In DIC, multiple factors are consumed in consumptive coagulopathy, prolonging both PT and APTT, with accompanying findings such as thrombocytopenia, reduced fibrinogen, and elevated D-dimer. In liver disease, multiple coagulation factors synthesized in the liver are reduced simultaneously, prolonging both PT and APTT, and fibrinogen may also be reduced. In vitamin K deficiency or warfarin use, the vitamin K–dependent factors (FII, FVII, FIX, FX) are all reduced, and PT tends to be more prolonged than APTT. After these acquired causes are excluded, FV:C, FX:C, FII:C, and fibrinogen (Clauss method) are measured sequentially to differentiate isolated common pathway factor deficiencies (FV, FX, FII, FI). If only FV:C is markedly reduced and the other factors are normal, FV deficiency (Owren disease) can be confirmed.
FV:C is quantified by single-factor FV:C assay (one-stage APTT- or PT-based method), and severity is classified: FV:C <1 IU/dL (severe), 1–10 IU/dL (moderate), 10–50 IU/dL (mild), 50–70 IU/dL (heterozygous carrier range). To assess the contribution of platelet FV, some specialized centers perform platelet FV testing. Platelets are washed to remove plasma, and FV:C is measured in the platelet lysate. When platelet FV:C is in the normal range and only plasma FV:C is low, bleeding may be mild owing to the complementary contribution of platelet FV. Conversely, when platelet FV:C is also low, a more severe bleeding tendency is expected, and adding platelet transfusion to FFP is considered in treatment. If PT and APTT correct on the mixing test, factor deficiency is suggested; if they do not correct, an inhibitor or antiphospholipid antibodies are suspected.
Besides congenital FV deficiency, acquired FV deficiency, in which autoantibodies (inhibitors) to FV develop, rarely occurs. Reported exposure causes of acquired FV deficiency include bovine thrombin (used as a hemostatic agent during surgery; antibodies to bovine-derived FV cross-react), antibiotics (especially aminoglycosides), hematologic malignancies, and autoimmune diseases. Clinically, when PT and APTT are suddenly prolonged and FV:C is markedly reduced, congenital and acquired forms are distinguished by confirming that previously normal coagulation function has suddenly changed. With acquired FV inhibitors, PT and APTT do not correct on the mixing test (because the inhibitor also neutralizes the FV of normal plasma), and the inhibitor titer can be quantified with the Bethesda assay. Treatment uses removal of the underlying cause together with immunosuppression (corticosteroids, cyclophosphamide, rituximab), plasma exchange, and platelet transfusion (platelet FV may be protected from antibodies).
The most common clinical starting point for screening for Owren disease is when prolongation of both PT and APTT is found during preoperative or bleeding evaluation. The most common acquired causes of simultaneous PT and APTT prolongation are liver disease, DIC, and vitamin K deficiency/warfarin, so these are systematically excluded first. Whether PT and APTT correct after vitamin K administration (5–10 mg IV) is checked, and liver function tests and a DIC panel (D-dimer, platelets, fibrinogen) are performed. If PT and APTT prolongation persists after these acquired causes are excluded and fibrinogen is normal, the possibility of common pathway factor (FV, FX, FII) deficiency is considered and single-factor assays are performed. There is an empirical guideline that when APTT prolongation is disproportionately severe compared with PT prolongation (PT >> APTT), FVII deficiency is more likely, and when both tests are similarly prolonged, common pathway factor deficiency is more likely.
The order of differentiating common pathway factor deficiencies after DIC and liver disease are excluded may vary with the clinical situation, but it is generally efficient to measure FV:C first. FV is synthesized in the liver but is not vitamin K–dependent, so the characteristic that it remains normal in vitamin K deficiency/warfarin can be used for differentiation. In vitamin K deficiency/warfarin, FII, FVII, FIX, and FX are reduced, but FV and FI (fibrinogen) are vitamin K–independent and therefore normal, so measuring FV can distinguish vitamin K–dependent multifactor reduction from isolated FV deficiency. FX:C and FII:C are measured together to check for combined deficiency (liver disease, VKCFD, F5F8D). If fibrinogen (Clauss method) is reduced, fibrinogen deficiency or dysfibrinogenemia is differentiated at the same time.
Besides incidental preoperative discovery, in patients with a bleeding history such as recurrent nosebleeds, excessive bleeding after surgery, menorrhagia, muscle hematomas, or joint bleeding, systematic bleeding history scoring using the ISTH-BAT (bleeding assessment tool) is performed, and if the score is abnormal (adult men ≥4 points, adult women ≥6 points), further coagulation testing is carried out. If simultaneous PT and APTT prolongation is confirmed on the coagulation panel, the differentiation process described above is followed. When there is a family history—one parent is an FV deficiency carrier, or a sibling has been diagnosed with FV deficiency—it is also advisable to measure FV:C proactively. In neonates with a family history of FV deficiency, FV:C is measured at birth or early on to determine whether severe deficiency is present and to plan early management.
In patients with confirmed FV deficiency, it is clinically important to check whether the FV Leiden variant coexists. In compound heterozygous patients (FV deficiency variant on one allele, FV Leiden on the other allele), all residual FV consists of FV Leiden and shows APC resistance, so there may be a thrombotic risk. Coexisting FV Leiden is checked with the activated protein C resistance test or FV Leiden–specific PCR/genetic analysis. If FV Leiden coexists, the balance between the indication for anticoagulant treatment and treatment of bleeding must be carefully assessed. Measuring FVIII:C together is also recommended to differentiate F5F8D (combined FV+FVIII deficiency).
The stepwise approach for definitive diagnosis of Owren disease (FV deficiency) is as follows. Step 1: confirm prolongation of both PT and APTT (normal TT, normal platelets). Step 2: exclude acquired causes with a DIC panel (D-dimer, platelets, fibrinogen), liver function tests, and a test of response to vitamin K administration. Step 3: distinguish factor deficiency (corrected) from an inhibitor (not corrected) with a mixing test (patient plasma + normal plasma 1:1). Step 4: measure FV:C, FX:C, FII:C, and fibrinogen (Clauss method) to confirm isolated FV deficiency (only FV:C markedly reduced, others normal). Step 5: measure FVIII:C to differentiate F5F8D. Step 6: distinguish CRM+/CRM− by measuring FV antigen (FV:Ag). Step 7: platelet FV:C measurement (optional). Step 8: identify pathogenic variants by F5 gene analysis (Sanger sequencing or NGS panel). Step 9: check for a coexisting FV Leiden variant (APC resistance or F5 Leiden–specific test).
The standard single-factor FV:C assay is the one-stage method (PT- or APTT-based method using FV-deficient substrate plasma). Classification of deficiency severity: FV:C <1 IU/dL (severe, spontaneous bleeding possible), 1–10 IU/dL (moderate, excessive bleeding with hemostatic stress), 10–50 IU/dL (mild, bleeding possible with major surgery), 50–70 IU/dL (heterozygous carrier range). The half-life of FV is about 12–36 hours, relatively moderate, so the effect after FFP administration lasts from several hours to more than a day. To identify heterozygous carriers, FV:C is measured in the parents, and if both parents have FV:C of 40–65%, they are considered heterozygous carriers. Combining genetic analysis with FV:C allows homozygous deficiency to be distinguished from compound heterozygous deficiency.
F5 gene analysis is performed for definitive diagnosis and genetic counseling when FV:C is clinically markedly reduced. Because the F5 gene is a large gene of 25 exons, an NGS-based rare bleeding disorder panel is more efficient than Sanger sequencing. After variant identification, pathogenicity classification is checked in recognized databases such as the Fibrinogen Mutation Database, ClinVar, and HGMD. F5 gene analysis can also determine whether the FV Leiden (Arg506Gln) variant is present. Genetic analysis distinguishes homozygosity (two copies of the same variant), compound heterozygosity (two different variants), or a combination of an FV deficiency variant + FV Leiden. In family testing, targeted testing for the patient's specific variant is efficient.
When both FV and FVIII are moderately reduced (FV:C and FVIII:C both about 5–30 IU/dL), F5F8D (combined FV+FVIII deficiency) must be differentiated. Because F5F8D is caused by variants in the LMAN1 or MCFD2 genes rather than the F5 or F8 genes, if no pathogenic variants are found on F5 and F8 gene analysis, LMAN1 and MCFD2 gene analysis is added. In F5F8D, FFP administration replaces both FV and FVIII, so treatment is the same as for isolated FV deficiency, but both factors must be monitored regularly to assess severity. The prevalence of F5F8D is much lower than that of isolated FV deficiency or isolated FVIII deficiency, but relatively high frequencies have been reported in specific populations (Ashkenazi Jews, Iran, etc.).
The greatest clinical limitation in treating Owren disease (FV deficiency) is that no dedicated FV concentrate is commercially available anywhere in the world. Therefore, the main current treatment for FV deficiency is fresh frozen plasma (FFP). FFP contains about 1 IU/mL of FV, and the dose is calculated according to the target FV:C level. Generally, the initial dose is 15–20 mL/kg, which can raise FV:C to about 15–20 IU/dL. For preoperative prophylaxis, the goal is to maintain FV:C at 25–50 IU/dL or higher, and for acute intracranial hemorrhage a higher level of 50–100 IU/dL is targeted. Because the half-life of FFP is 12–36 hours, major surgery requires repeated doses at 12–24-hour intervals for 24–48 hours after surgery. Limitations of FFP include the risk of volume overload with large-volume administration, transfusion-related complications (allergic reactions, TRALI, risk of viral transmission), and difficulty of accurate FV:C monitoring.
Because FV is stored in platelet alpha granules, platelet transfusion is a means of replacing FV together with or as an alternative to FFP. FV contained in platelets is released locally upon platelet activation even when plasma FV:C is low, contributing directly to thrombin generation at the site of injury. Platelet transfusion increases efficacy when combined with FFP, particularly when FFP alone does not achieve sufficient hemostasis or in patients whose platelet FV:C is also reduced. In fact, some experts recommend combined administration of FFP and platelets for preoperative prophylaxis in severe FV deficiency. An appropriate platelet product is selected considering adverse effects related to transfused platelets (fever, allergic reactions, antibody formation against platelet alloantigens, risk of CMV transmission).
Cryosupernatant is the plasma component remaining after removal of cryoprecipitate and contains FV (cryoprecipitate is concentrated mainly in FVIII, FXIII, vWF, fibrinogen, and fibronectin). Cryosupernatant has lower FVIII and vWF content than FFP and is used to treat TTP (thrombotic thrombocytopenic purpura), but because its FV content is preserved, it can be used as an alternative in FV deficiency. However, like FFP, it is a plasma-derived product and carries volume problems and the risk of viral transmission. In resource-limited settings, cryosupernatant can be an alternative FV source when FFP is in short supply. If recombinant FV or semisynthetic FV concentrates are developed in the future, the treatment environment will improve greatly, but research on developing FV concentrates is still at an early stage.
In severe FV deficiency (FV:C <1 IU/dL), long-term prophylaxis may be attempted to prevent intracranial hemorrhage, but long-term prophylaxis is realistically very difficult because of the short half-life and adverse effects of FFP. Long-term prophylaxis with FFP requires administration 2–3 times a week or every other day, which entails the burden of regular large-volume intravenous infusions and the resulting volume overload, transfusion-related reactions, and complications related to venous access. Because of this difficulty, long-term management of severe FV deficiency is much more limited than for FXIII deficiency or hemophilia A and B. There are reports that regular prophylactic FFP administration contributed to preventing intracranial hemorrhage in some pediatric patients, but no standardized long-term prophylaxis protocol has been established. Considering the difficulty of treating FV deficiency, the development of a dedicated FV concentrate or recombinant FV remains a clinically urgent unmet medical need.
The prognosis of Owren disease (FV deficiency) varies greatly with the severity of deficiency and access to appropriate treatment. Most patients with mild disease (FV:C >10 IU/dL) can live normally, and complications can be prevented with advance preparation for high-risk surgery or childbirth. In patients with moderate disease (1–10 IU/dL), bleeding can mostly be controlled with appropriate FFP administration during hemostatic stress such as surgery or trauma. The prognosis is poorest in severe deficiency (FV:C <1 IU/dL), and if intracranial hemorrhage occurs, the patient may die or be left with permanent neurological damage. In severe deficiency, the difficulty of long-term prophylaxis sometimes prevents adequate prevention of intracranial hemorrhage, and this is the main reason Owren disease is harder to treat than other coagulation factor deficiencies. The reality of having to rely on FFP in the absence of a dedicated FV concentrate remains an important barrier to improving prognosis.
When inhibitors (alloantibodies) to FV develop in patients with congenital FV deficiency, treatment becomes extremely difficult. When an FV inhibitor develops, FFP administration becomes ineffective and the main existing treatment is lost. Treatment options when an inhibitor develops include immunosuppression (high-dose corticosteroids, cyclophosphamide, rituximab), plasma exchange (inhibitor removal), platelet transfusion (platelet FV may be partly protected from the inhibitor), and recombinant FVIIa (rFVIIa, bypassing therapy). When the inhibitor titer is low, immunosuppression can eliminate the inhibitor, but treatment is very difficult with high-titer inhibitors. With acquired FV inhibitors, removal of the underlying cause (stopping exposure to bovine-derived thrombin, discontinuing the causative drug, etc.) and immunosuppression usually eliminate the inhibitor within weeks to months.
When recurrent joint bleeding occurs in severe FV deficiency, hemophilic arthropathy similar to that of hemophilia A and B can progress. Joint damage causes cartilage erosion, joint stiffness, and chronic pain, markedly reducing quality of life. Appropriate physical therapy and rehabilitation exercise are important for preserving joint function. In children with severe FV deficiency, the need to restrict physical activity for growth and development can negatively affect normal development. Psychosocial support is also important, and age-appropriate education should be provided, especially so that patients acquire the ability to understand and manage their condition. Because of the limitation of FFP-only treatment, home treatment is difficult and hospital dependence increases, which negatively affects patients' quality of life.
In women with FV deficiency, pregnancy and childbirth are managed through regular FV:C monitoring and delivery planning. During pregnancy, FV:C rises slightly physiologically (to 20–50 IU/dL in some patients), so the bleeding risk may be relatively low in the second and third trimesters. However, because FV:C falls sharply after delivery, FFP is prepared just before delivery and given at or immediately after delivery to prevent postpartum hemorrhage. Epidural anesthesia can be performed safely only when FV:C is maintained at a minimum of 50 IU/dL or higher, so this must be discussed with the obstetric anesthesia team when planning delivery. Successful pregnancy and delivery are possible under appropriate hematologist management, and successful deliveries in mothers with FV deficiency have been reported internationally.
When a patient with Owren disease (FV deficiency) undergoes any surgery or invasive procedure, an FV replacement plan must be established in advance in consultation with a hematologist. The target FV:C and FFP dose are calculated according to the scale of surgery, and whether to add platelet transfusion is decided. The target FV:C is set at 15–25 IU/dL for minor surgery, 25–50 IU/dL for intermediate surgery, and 50–100 IU/dL for major surgery (brain surgery, major intra-abdominal surgery, etc.). FFP is given at 15–20 mL/kg just before surgery, FV:C is monitored after surgery, and a plan is made for re-dosing at 12–24-hour intervals to maintain the target level. If excessive bleeding occurs during or after surgery, additional FFP is given and platelet transfusion is considered. Combined use of tranexamic acid as adjunctive treatment can help increase the stability of fibrin clots by inhibiting fibrinolysis.
In patients with severe FV deficiency (FV:C <1 IU/dL), prevention of intracranial hemorrhage is the most important goal of long-term management. FFP-based long-term prophylaxis is realistically difficult, but attempts are being made in severe pediatric patients to maintain FV:C at a certain level with FFP administration 1–2 times a week. From a preventive standpoint, it is important to educate patients with severe deficiency to recognize early symptoms of intracranial hemorrhage (sudden headache, vomiting, seizures, altered consciousness) and to go to the emergency department immediately. Patients or caregivers are advised to carry an emergency medical card or bracelet stating "I have factor V deficiency (Owren disease/parahemophilia) and need fresh frozen plasma (FFP) in a bleeding emergency." They are advised to avoid contact sports and activities with a high risk of head trauma.
No method has yet been established to prevent the development of inhibitors to FV in patients with FV deficiency. Because cases have been reported in which antibodies to bovine FV formed after the use of bovine-derived thrombin during surgery and cross-reacted to produce human FV inhibitors, avoiding the use of bovine-derived thrombin is one prevention strategy. There is a risk of alloantibody formation against FV with repeated FFP administration, but because FFP is currently the only main means of treating FV deficiency, this risk must be accepted. To detect possible inhibitor development early, regular measurement of FV:C before and after FFP administration and monitoring for inhibitors with mixing tests are recommended.
Genetic counseling is provided to the families of patients with FV deficiency. The counseling covers the autosomal recessive mode of inheritance, the probability (25%) of a completely deficient child being born to heterozygous parents, the possibility of identifying carriers through confirmation of F5 gene variants, prenatal diagnosis options, and so on. Patients with FV deficiency planning pregnancy or heterozygous carrier couples are informed about the possibility of prenatal genetic testing. When FV Leiden coexists, its clinical significance (increased thrombotic risk) is also discussed. For couples in which each carries one allele of FV deficiency or FV Leiden (one is an FV deficiency carrier and the other an FV Leiden carrier), it is explained that 25% of children may be compound heterozygous (FV deficiency + FV Leiden), and that in this case the child may have a combined risk of bleeding (FV deficiency side) and thrombosis (FV Leiden side). When FV deficiency is confirmed in the family, members are educated to always inform the attending physician before surgery and to carry an emergency card.